Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cullinan Therapeutics, Inc. (CGEM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.80-13.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CGEM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash runway extended into 2029 | The company has cash to last into 2029. | Intact | Cash resources fall below level needed to fund operations into 2029 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CGEM is a speculative, clinical-stage biotechnology company, so its multi-year case depends on development and regulatory milestones rather than established earnings. The thesis is in a watch state, and confidence in the overall read is low.
The evidence gives no valuation measure or clear account of what the market already assumes, so whether CGEM is cheap or expensive versus peers cannot be assessed. No valuation fragility signals fired, but that does not resolve the expectations gap.
Near term, performance is mixed: CGEM had an earnings miss in August, and its recent financial performance is below its industry cohort. Management is pursuing a zipalertinib NDA submission by year-end 2026, with a stated regulatory milestone in February 2027, while clinical data milestones for CLN-978 and velinotamig are forthcoming. The next print carries elevated miss risk, and guidance cuts would be a meaningful negative.
The multi-year thesis hinges on progress toward U.S. approval for zipalertinib and useful clinical data for the autoimmune programs. Near-term risks include a guidance cut and weakening employment data, while continued strong results and higher guidance from sector bellwethers could support the healthcare backdrop.
Over the next one to three years, CGEM remains a milestone-driven, high-risk thesis with management priorities underway but results and upcoming evidence still uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Cullinan is advancing its CLN-978 clinical trials for tough autoimmune diseases. |
| Intact |
| Trial progress stalls or clinical data fails to show benefit |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce losses in EPS | A supporting condition in Cullinan Therapeutics, Inc.'s published investment case. The stated target is EPS loss less than -$3.0 in FY26 and improving in FY27. | Intact | EPS loss worsens beyond -$3.0 in FY26 or FY27 | Diluted EPS: $-0.81 per share FY2026-Q2; GAAP. Published target: EPS loss less than -$3.0 in FY26 and improving in FY27. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 6, 2026-0.81 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.53 → $-2.47 · observed estimates
$0.04B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-07-25 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-07-26 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-07-27 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-07-28 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-07-29 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-07-30 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-07-31 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-08-01 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-08-02 | $-2.53 | $40,391,550 | 8 / 10 |
| 2026-08-03 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-04 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-05 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-06 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-07 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-08 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-09 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-10 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-11 | $-2.54 | $50,519,440 | 8 / 8 |
| 2026-08-12 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-13 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-14 | $-2.41 | $47,709,462 | 7 / 7 |
| 2026-08-15 | $-2.41 | $47,709,462 | 8 / 7 |
| 2026-08-16 | $-2.41 | $47,709,462 | 8 / 7 |
| 2026-08-17 | $-2.41 | $47,709,462 | 8 / 7 |
| 2026-08-18 | $-2.41 | $47,709,462 | 8 / 7 |
| 2026-08-19 | $-2.41 | $47,709,462 | 8 / 7 |
| 2026-08-20 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-21 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-22 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-23 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-24 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-25 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-26 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-27 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-28 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-29 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-30 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-08-31 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-01 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-02 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-03 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-04 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-05 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-06 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-07 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-08 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-09 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-10 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-11 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-12 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-13 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-14 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-15 | $-2.62 | $45,521,446 | 8 / 8 |
| 2026-09-16 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-17 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-18 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-19 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-20 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-21 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-22 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-23 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-24 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-25 | $-2.60 | $47,829,139 | 8 / 8 |
| 2026-09-26 | $-2.66 | $47,838,292 | 8 / 8 |
| 2026-09-27 | $-2.66 | $47,838,292 | 8 / 8 |
| 2026-09-28 | $-2.66 | $47,838,292 | 8 / 8 |
| 2026-09-29 | $-2.66 | $47,838,292 | 8 / 8 |
| 2026-09-30 | $-2.66 | $47,838,292 | 8 / 8 |
| 2026-10-01 | $-2.66 | $47,838,292 | 8 / 8 |
| 2026-10-02 | $-2.66 | $47,838,292 | 8 / 8 |
| 2026-10-03 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-04 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-05 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-06 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-07 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-08 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-09 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-10 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-11 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-12 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-13 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-14 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-15 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-16 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-17 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-18 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-19 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-20 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-21 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-22 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-23 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-24 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-25 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-26 | $-2.50 | $57,838,292 | 8 / 8 |
| 2026-10-27 | $-2.47 | $60,145,985 | 8 / 8 |
| 2026-10-28 | $-2.47 | $60,145,985 | 8 / 8 |
| 2026-10-29 | $-2.47 | $60,145,985 | 8 / 8 |
| 2026-10-30 | $-2.47 | $60,145,985 | 8 / 8 |
| 2026-10-31 | $-2.47 | $60,145,985 | 8 / 8 |
| 2026-11-01 | $-2.47 | $60,145,985 | 8 / 8 |
| 2026-11-02 | $-2.47 | $60,145,985 | 8 / 8 |
| 2026-11-03 | $-2.47 | $60,145,985 | 8 / 8 |
| 2026-11-04 | $-2.47 | $60,145,985 | 8 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.